MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

On November 17, 2026 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). THIO-101 Part C is evaluating additional patients to confirm the strong efficacy data observed in Parts A and B of the study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 2 trial assesses advanced NSCLC patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients are treated with ateganosine 180mg followed by cemiplimab (Libtayo) in cycles of 21 days. The sequential administration of ateganosine followed by PD-(L)1 inhibition is intended to enhance and prolong the antitumor immune response.

"It is encouraging to see an 88% disease control rate (DCR) as the THIO-101 data continue to mature. DCR serves as an excellent data surrogate for Overall Survival (OS) efficacy according to a historical meta-analysis1 and our own analysis of previous data," said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. "To date, the trial’s combined study data have consistently demonstrated stable disease or better at the first tumor assessment following treatment initiation. Importantly, the Part C interim efficacy results are well aligned with the outcomes observed in Parts A and B, now across a substantially larger patient population. Consistency of the results as our patient pool expands further strengthens the compelling efficacy signals we are seeing for both of our trials in NSCLC."

For Parts A, B, and C of THIO-101 as of October 01, 2026, the observed disease control rate (DCR) for third-line NSCLC patients resistant to chemo and immunotherapy is 88% (38 of 43 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment. This DCR measure contrasts with reported 25%–35% disease control for standard 3L chemotherapy regimens.1

MAIA has completed enrollment in Part C of its Phase 2 THIO-101 expansion, which enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and in the United States. Concurrently, an ongoing pivotal Phase 3 clinical trial of third line ateganosine treatment, THIO-104, with the same target population as THIO-101 Part C, is advancing toward regulatory milestones including 2027 interim survival analysis.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

(Press release, MAIA Biotechnology, NOV 17, 2026, View Source [SID1234674899])

Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib

On November 17, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Merck is discontinuing the Phase 3 BELLWAVE-011 trial (NCT06136559) following review of the results by an external Data Monitoring Committee (eDMC) that suggested the benefits may not outweigh the risks in this study. Merck subsequently confirmed this following a review of the data in its totality, and as a result of this analysis, Merck has also made the decision to discontinue the broader BELLWAVE clinical development program, including the other Phase 3 studies: BELLWAVE-008 and BELLWAVE-010.

Merck is informing study investigators for these clinical trials and advises patients to speak to their study team and physician regarding next steps and treatment options. Data analyses for these trials are ongoing, and the results will be shared with the scientific community.

"Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program. We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible," said Dr. Marjorie Green, senior vice president and head of global oncology clinical development, Merck Research Laboratories. "We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers."

About nemtabrutinib (MK-1026)

Nemtabrutinib is an investigational, oral, non-covalent BTK inhibitor that suppresses oncogenic B-cell receptor signaling. Nemtabrutinib was evaluated in clinical trials, including BELLWAVE-001 (NCT03162536), BELLWAVE-008 (NCT05624554), BELLWAVE-011 (NCT06136559), BELLWAVE-010 (NCT05947851), BELLWAVE-003 (NCT04728893), BELLWAVE-015 (NCT06442436), BELLWAVE-027 (NCT07734610) and waveLINE-006 (NCT05458297).

(Press release, Merck & Co, NOV 17, 2026, View Source [SID1234674882])

NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100

On November 17, 2026 NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma. One additional partial response brought the objective response rate to 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) in the August 12, 2026 topline results. Both rates were assessed using RANO 2.0 criteria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By RANO 2.0 criteria, three patients had a partial response (12.5%), 13 had stable disease (54.2%) and eight had progressive disease (33.3%). The disease control rate was 66.7%. Five patients remained on treatment at the interim database lock.

As previously reported, six-month progression-free survival, the study’s primary endpoint, was 48.9% (95% CI, 26.3%–68.1%) by RANO 2.0 using Kaplan–Meier estimation, compared with the prespecified 20% historical benchmark (one-sided p = 0.0047). Median overall survival was 26.1 months (95% CI, 8.5–27.1 months) from the start of NEO100 treatment at recurrence. The single-arm, open-label study used a historical benchmark and had no randomized control group. Results differ under the response criteria and estimation method specified in the study protocol. Interim results may change at final analysis.

"We are encouraged by the additional partial response in this update," said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "We remain focused on advancing the development of NEO100 for patients with recurrent high-grade glioma."

At the interim analysis, all reported treatment-related adverse events were Grade 1 or 2 and consisted predominantly of local nasal or upper-airway effects. NeOnc reported no treatment-related serious adverse events or discontinuations due to treatment-related adverse events.

About the NEO100-01 Study

NEO100-01 is an open-label, multicenter Phase 1/2a study of intranasal NEO100 in patients with radiographically confirmed progression or recurrence of primary or secondary Grade IV glioma or Grade III astrocytoma harboring an IDH1 mutation. In Phase 2a, 28 patients received the recommended Phase 2 dose of 1,152 mg/day. The efficacy population consisted of 24 patients with IDH1-mutant tumors, including 21 with Grade IV disease. Enrollment is complete.

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established. NEO100 has received Orphan Drug designation from the FDA for the treatment of gliomas.

(Press release, Neonc, NOV 17, 2026, View Source [SID1234674900])

Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

On November 17, 2026 Servier reported extended follow-up results and subgroup analyses from the Phase 3 INDIGO trial evaluating VORANIGO (vorasidenib) in mutant isocitrate dehydrogenase 1 or 2 (IDH1/2) glioma who received treatment following surgery as their primary therapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia. These analyses provide longer-term insights into VORANIGO’s clinical benefit across evaluated subgroups. Alongside these data, an exploratory analysis of seizure activity and quality of life among INDIGO patients was also presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated Phase 3 INDIGO results include analyses of 144 of 163 patients randomized to placebo who crossed over to VORANIGO from placebo by the January 17, 2025 data cutoff, along with analyses by histology in oligodendroglioma and astrocytoma. These results build on findings previously reported at ASCO (Free ASCO Whitepaper), which demonstrated continued benefit in progression-free survival (PFS) at a median follow-up time of 41.6 months.

"The results from the INDIGO analyses presented at SNO reinforce the clinical benefit of VORANIGO in patients with Grade 2 IDH-mutant glioma, with the crossover patient population data demonstrating consistent results," said Islam Hassan, M.D., MSc., Global Head of Development, Neuro-Oncology at Servier. "Together with the data on VORANIGO’s impact on quality of life, these findings strengthen our understanding of the impact of VORANIGO over time and underscore its important role in glioma care."

Efficacy data and subgroup analyses after extended follow-up with vorasidenib in INDIGO – a global, randomized, placebo-controlled, double-blinded, Phase 3 trial in grade 2 mutant isocitrate dehydrogenase 1/2 (mIDH1/2) glioma — November 14, 5:00–5:07 p.m. EST

The latest results from this analysis were presented by Timothy F. Cloughesy, M.D., David Geffen School of Medicine, Department of Neurology, University of California, Los Angeles, an investigator for the INDIGO trial. These data showed clinical benefit among patients who crossed over from placebo and across subgroups defined by histologic subtype. Key findings include:

Among patients who crossed over to VORANIGO, median PFS per investigator was 37.2 months overall (95% CI, 33.4-not estimable [NE]). Among patients with astrocytoma who crossed over, median PFS by investigator was 37.2 months (95% CI, 25.6-NE) and in patients with oligodendroglioma who crossed over, median PFS by investigator was not reached (95% CI, 24.6-NE). Median PFS per investigator was 33.4 months (95% CI, 24.6 months-NE) for patients with progressive disease (PD) at crossover and was NE for patients with no PD at crossover.
In a post-hoc analysis of patients who crossed over to VORANIGO from placebo, VORANIGO reversed average tumor growth; tumor volume increased on average by 16.1% per six months before crossover and decreased on average by 2.9% per six months after crossover. The shift from growth to shrinkage was observed in both oligodendroglioma and astrocytoma subgroups.
The substantial increase in objective response rate (ORR) by blinded independent review committee (BIRC) over time for the overall population (from 10.7% [95% CI, 6.5%–16.4%] in September 2022 to 20.8% [95% CI, 15.0%–27.8%] in January 2025) is reflected in patients with astrocytoma (increase from 7.5% [95% CI, 2.8%–15.6%] to 17.5% [95% CI, 9.9%–27.6%]) as well as those with oligodendroglioma (increased from 13.6% [95% CI, 17.2 %-22.6%] to 23.9% [95%, CI, 15.4%–34.1%]).
The safety profile remained consistent with previous data cutoffs with no new safety signals identified during extended follow-up or in crossover patients. Grade >3 treatment-emergent adverse events (TEAEs) occurred in 31.7% of patients randomized to VORANIGO and 20.1% of those crossed over from placebo. The most commonly reported Grade >3 TEAEs were increased alanine aminotransferase (10.8% and 7.6%), increased aspartate aminotransferase (4.8% and 3.5%), seizure (4.8% and 4.2%) and increased gamma-glutamyltransferase (GGT; 3% and 0.7%). There were no treatment-related deaths in either group, and TEAEs leading to discontinuation were uncommon among patients randomized to VORANIGO (4.8%) and those who crossed over from placebo (2.1%).
"Longer follow-up from INDIGO continues to demonstrate the durable clinical benefit of IDH-inhibition for patients with Grade 2 IDH-mutant glioma across patient subgroups," said Dr. Timothy Cloughesy. "These findings also show promising results in patients who crossed over from placebo, including those whose disease had already progressed, providing further insight into the potential role of IDH inhibition to help manage disease over time."

Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from Phase 3 INDIGO study — November 15, 11:07–11:14 a.m. EST

An exploratory analysis presented as an encore by Wolfgang Wick, M.D., Universitätsklinikum Heidelberg & German Cancer Research Center, examined seizure activity and quality of life in INDIGO participants who experienced at least one seizure in the baseline and/or on-treatment periods. At the January 17, 2025, data cutoff:

In the overall population of patients treated with VORANIGO, the proportion of patients with on-treatment seizures remained stable from March 2023 to January 2025 (98.1% vs 98.2%). Moreover, the seizure rate with VORANIGO decreased from 18.2 (95% CI, 8.4–39.5) to 15.9 (95% CI, 9.1–27.1) seizures per person-year between March 2023 and January 2025.
The rate ratio versus placebo improved from 0.36 (95% CI, 0.14–0.89; P=0.0263) to 0.28 (95% CI, 0.14–0.55; P=0.0002), supporting a sustained treatment effect with longer follow-up.
VORANIGO was associated with long-term stabilization of seizure frequency overall and across both oligodendroglioma and astrocytoma. Patients with oligodendroglioma treated with VORANIGO showed a trend towards low, stable seizure counts and patients with astrocytoma experienced low seizure counts regardless of treatment.
VORANIGO was associated with sustained preservation of quality of life, with exploratory analyses in patients with >1 seizure, showing a lower risk of worsening versus placebo on the Functional Assessment of Cancer Therapy–Brain (FACT-Br) scale (HR=0.38; 95% CI, 0.15–1.00) and its brain cancer subscale (HR=0.32; 95% CI, 0.11–0.91).

(Press release, Servier, NOV 17, 2026, View Source [SID1234674883])

Vittoria Biotherapeutics to Present Phase 1 Results for Senza5 CART5 in T-Cell Lymphoma in an Oral Session and LampTAC Degrader Platform Data in a Poster Session at ASH 2026

On November 17, 2026 Vittoria Biotherapeutics, Inc. reported that results from the Phase 1 VIPER-101 study of Senza5 CART5 in relapsed or refractory T-cell lymphoma will be presented in an oral session, and preclinical data on its LampTAC protein degradation platform will be presented in a poster session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will highlight clinical activity, CAR-T persistence, immune reconstitution, and delayed immune-mediated adverse events in heavily pre-treated patients with relapsed or refractory T-cell lymphoma. The presentation follows Vittoria’s announcement of U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for Senza5 CART5, which was supported by this dataset, in addition to Orphan Drug designation.

"The responses we have seen in VIPER-101 strengthen our conviction that Senza5 CART5 can become a meaningful option for patients with relapsed or refractory T-cell lymphoma, who today have few effective choices," said Nicholas A. Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics.

A separate poster will describe LampTAC, a modular, genetically encoded protein degradation platform that enables cell-intrinsic protein control without genome editing and presents data supporting its potential for armoring in vivo CAR-T cells. Together, the presentations reflect Vittoria’s progress in building next-generation immunotherapies with a shared foundation in T-cell biology.

"Our work on CD5 has shown that modulating T-cell signaling pathways can make engineered T cells more potent. LampTAC is the evolution of that finding: a programmable, cell intrinsic protein degrader technology that can enhance in vivo engineered cells without genome editing. We look forward to presenting both datasets at ASH (Free ASH Whitepaper), and to advancing the distinct opportunities each represents," added Dr. Siciliano.

ASH 2026 Presentation Highlights and Details

VIPER-101 – Oral Presentation

Presentation title: High complete response rates, durable CD5-negative T-cell persistence, and mechanistically tractable delayed immune-mediated toxicity after low-dose CD5-edited CD5 CAR T-cell therapy in relapsed/refractory T-cell lymphoma
Presenter: Stefan K. Barta, M.D., M.S., Penn Medicine
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies
Abstract / publication number: 908
Date, time and location: Monday, December 14, 2026; 3:00 to 3:15 PM CT (session 2:45 to 4:15 PM); Ernest N. Morial Convention Center, New Orleans Theatre B

LampTAC – Poster Presentation

Presentation title: LAMPTAC: A genetically encoded lysosome-targeting chimera platform for programmable, cell-intrinsic protein degradation can enable multiplexed engineering of in vivo CAR-T cells for heme indications
Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III
Abstract / publication number: 5902
Date, time and location: Monday, December 14, 2026; 6:00:00 – 8:00:00 PM CT; MCCNO – Hall F

(Press release, viTToria biotherapeutics, NOV 17, 2026, View Source [SID1234674901])